Trial Profile
Reversing poor graft function with eltrombopag after allogeneIc hematopoietic cell transplantation : a prospective, phase II study by the SFGM-TC
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Nov 2023
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Thrombocytopenia
- Focus Therapeutic Use
- Acronyms REGALIA
- 17 Nov 2023 This trial has been discontinued in France according to European Clinical Trials Database record.
- 18 Aug 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2023.
- 18 Aug 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2023.